For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just curb their desire to eat; for some, they also lead them to drink less alcohol.

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of alcohol consumed when someone on the drug does drink

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a small trial, researchers reported on Wednesday.